SCHEMBL4185694

SCHEMBL4185694

O=C(Cc1ccccc1Cl)c1c(O)c2cccnc2n(-c2cccc(C(F)(F)F)c2)c1=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 2/20 0.47
POLB P06746 2/20 0.47
MAPT P10636 7/20 0.42
TRPV1 Q8NER1 1/20 0.41
PDE4B Q07343 1/20 0.39
PDE4D Q08499 1/20 0.39
LMNA P02545 1/20 0.39
CCKBR P32239 1/20 0.38
NR2E1 Q9Y466 1/20 0.38
NPY5R Q15761 1/20 0.38
KDM4E B2RXH2 2/20 0.37
ALDH1A1 P00352 2/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
NPC1 O15118 1/20 0.37
HSP90AA1 P07900 1/20 0.37
HTT P42858 1/20 0.37
CASP6 P55212 1/20 0.37
TDP1 Q9NUW8 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4187214 0.90 POLB (0.45) TP53POLBMAPTTRPV1PDE4B
SCHEMBL4182715 0.90 TP53 (0.45) TP53POLBMAPTTRPV1PDE4B
SCHEMBL4194573 0.88 MAPT (0.41) TP53POLBMAPTPDE4BPDE4D
SCHEMBL4187658 0.87 POLB (0.47) TP53POLBMAPTTRPV1PDE4B
SCHEMBL4182553 0.87 MAPT (0.48) TP53POLBMAPTTRPV1PDE4B
SCHEMBL4188055 0.87 MAPT (0.49) TP53POLBMAPTTRPV1PDE4B
SCHEMBL4190805 0.87 TP53 (0.43) TP53POLBMAPTTRPV1PDE4B
SCHEMBL4183574 0.86 TP53 (0.44) TP53POLBMAPTTRPV1PDE4B
SCHEMBL4183644 0.85 TP53 (0.43) TP53POLBMAPTTRPV1PDE4B
SCHEMBL4195071 0.84 CNR2 (0.44) TP53POLBMAPTTRPV1PDE4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1925617-B1 HETEROCYCLIC COMPOUND, AND PRODUCTION PROCESS AND USE THEREOF ASKA PHARM CO LTD (JP) 2012-11-14 EP disclosed
US-8193356-B2 Heterocycle compound, and production process and application thereof ASKA PHARMACEUTICAL CO., LTD. (JP) 2012-06-05 US disclosed
US-20090131467-A1 Heterocycle Compound, and Production Process and Application Thereof ASKA PHARMACEUTICAL CO., LTD. (JP) 2009-05-21 US disclosed
EP-1925617-A1 HETEROCYCLIC COMPOUND, AND PRODUCTION PROCESS AND USE THEREOF ASKA Pharmaceutical Co., Ltd. (JP) 2008-05-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131467-A1 Heterocycle Compound, and Production Process and Application Thereof PDE3B, PDE4B, PDE7A TP53 4856/4885POLB 1630/4885MAPT 4865/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.